Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer.

Josephine Louella Feliciano,Dylan McLoone,Yingxin Xu,Ruben G W Quek,Andreas Kuznik,Jean-Francois Pouliot,Giuseppe Gullo,Petra Rietschel,Patricia Guyot,Gerasimos Konidaris,Keith Chan,Sam Keeping,Florence R Wilson,Nick Freemantle

Frontiers in oncology（2022）

引用 3|浏览6

暂无评分

摘要

After adjusting for treatment crossover and continued cemiplimab treatment after progression with the addition of histology-specific chemotherapy observed in EMPOWER-Lung 1, cemiplimab continued to demonstrate a clinically important and statistically significant OS benefit versus chemotherapy, consistent with the primary analysis.

查看译文

关键词

EMPOWER-lung 1,cemiplimab,chemotherapy,crossover design,first-line treatment,non-small cell lung cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要